Citation Impact
Citing Papers
OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
2012 Standout
Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group Study
2003 Standout
Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data
1997 Standout
Where Does Serum Amylase Come From and Where Does It Go?
1990
Untangling the ErbB signalling network
2001 Standout
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer
2007 Standout
Survival Effect of Maximal Cytoreductive Surgery for Advanced Ovarian Carcinoma During the Platinum Era: A Meta-Analysis
2002 Standout
Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial
2015 Standout
Phase II and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer
1995
A Population-Based Study of Patterns of Care for Ovarian Cancer: Who Is Seen by a Gynecologic Oncologist and Who Is Not?
2002
Ifosfamide plus Cisplatin as Primary Chemotherapy of Advanced Ovarian Cancer
1997
Randomized Study Comparing Carboplatin/Cyclophosphamide and Cisplatin/Cyclophosphamide as First-Line Treatment in Patients with Stage III/IV Epithelial Ovarian Cancer and Small Volume Disease
1997
Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
1993
A meta-analysis of prognostic factors in advanced ovarian cancer with median survival and overall survival (measured with the log (relative risk)) as main objectives
1989
Highly Active Ansamitocin Derivatives: Mutasynthesis Using an AHBA‐Blocked Mutant
2008
Cardiac effects of adjuvant doxorubicin and radiation therapy in breast cancer patients.
1998
Regulation of the signal transduction program by drugs
1997
A Dose-Escalating Study of Weekly Bolus Topotecan in Previously Treated Ovarian Cancer Patients
2001
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer
2003 Standout
Carboplatin with cyclophosphamide in patients with advanced ovarian cancer: an efficacy and quality-adjusted survival analysis
1992
Ovarian cancer
2014 Standout
Meta-analysis of surgery in advanced ovarian carcinoma: Ismaximum cytoreductive surgery an independent determinant of prognosis?
1992
Cardiac Failure and Dysrhythmias 6–19 Years After Anthracycline Therapy: A Series of 15 Patients
1995
Advanced epithelial ovarian cancer: salvage whole abdominal irradiation for patients with recurrent or persistent disease after combination chemotherapy.
1988
Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer
1996 Standout
Classification of papillomaviruses
2004 StandoutNobel
Human ovarian cancer cell lines resistant to cisplatin, doxorubicin, and l-phenylalanine mustard are sensitive to Δ7-prostaglandin Δ1 and Δ12-prostaglandin J2
1991
A nomogram to predict postresection 5‐year overall survival for patients with uterine leiomyosarcoma
2011
Paclitaxel (Taxol)
1995 Standout
Second-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinoma.
1998
2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults
2009 Standout
Cancer of the Ovary
1993
Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program.
1993
Guideline for Prevention of Surgical Site Infection, 1999
1999 Standout
Intraperitoneal Cisplatin plus Intravenous Cyclophosphamide versus Intravenous Cisplatin plus Intravenous Cyclophosphamide for Stage III Ovarian Cancer
1996 Standout
Current Management Strategies for Ovarian Cancer
2007
Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial
2000
A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma
2008 Standout
Skin Cancers after Organ Transplantation
2003 Standout
Complete Cytoreductive Surgery Is Feasible and Maximizes Survival in Patients with Advanced Epithelial Ovarian Cancer: A Prospective Study
1998
A Critique of Surgical Cytoreduction in Advanced Ovarian Cancer
2000
Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials
1995
Hexamethylmelamine as second-line therapy in platin-resistant ovarian cancer
1992
Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group Study.
1989
A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian Cancer
2003
Effect of adjuvant chemotherapy on time to recurrence and survival of stage I uterine sarcomas
1988
Intraoperative tumor-specific fluorescence imaging in ovarian cancer by folate receptor-α targeting: first in-human results
2011 Standout
Novel, dose intensive, single-agent cisplatin in the first- line management of advanced stage ovarian cancer
1992
Advanced epithelial ovarian carcinoma: Long-term survival experience at the community hospital
1992
Potent Prostaglandin A1 Analogs That Suppress Tumor Cell Growth through Induction of p21 and Reduction of Cyclin E
1998 StandoutNobel
An Analysis of Two versus Three Grades for Endometrial Carcinoma
1999
Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
1989
Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study.
1994
Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience.
1991
Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer
1992
The impact of aggressive debulking surgery and cisplatin-based chemotherapy on progression-free survival in stage III and IV ovarian carcinoma.
1988
Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial
2000 Standout
Estrogen Resistance Caused by a Mutation in the Estrogen-Receptor Gene in a Man
1994 Standout
Acute Pancreatitis
1994 Standout
A Multigene Assay to Predict Recurrence of Tamoxifen-Treated, Node-Negative Breast Cancer
2004 Standout
Langerhans Cells and Epithelial Cell Modifications in Cervical Intraepithelial Neoplasia: Correlation with Human Papillomavirus Infection
1990
Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer
1988
Cardiac Myxomas
1995 Standout
Combined Carboplatin plus Ifosfamide and Cisplatin in Patients with Advanced Ovarian Carcinoma. A Phase I–II Study
1998
Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.
1992
Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphaide therapy in advanced ovarian adenocarcinoma
1994
Early versus Late Parenteral Nutrition in Critically Ill Adults
2011 Standout
High-dose cisplatin combination chemotherapy in the treatment of advanced epithelial ovarian carcinoma.
1990
Disruption of c-mos causes parthenogenetic development of unfertilized mouse eggs
1994 StandoutNatureNobel
Phylogenetic Classification of Human Papillomaviruses: Correlation With Clinical Manifestations
1992
Endometrial cancer
1997
Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings
1999
Quantifying heterogeneity in a meta‐analysis
2002 Standout
The effect of prolonged cisplatin-based chemotherapy on progression-free survival in patients with optimal epithelial ovarian cancer: “Maintenance” therapy reconsidered
1992
Long-Term Results in Patients with Advanced Epithelial Ovarian Carcinoma Treated with a Combination of Cisplatin, Doxorubicin, and Cyclophosphamide
1997
Doxorubicin-Induced Cardiomyopathy
1998 Standout
Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV Ovarian Cancer
2010 Standout
Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical Cancer
2003 Standout
Randomized trial of dose-intensity with single-agent carboplatin in patients with epithelial ovarian cancer. London Gynaecological Oncology Group.
1998
Chlorhexidine–Alcohol versus Povidone–Iodine for Surgical-Site Antisepsis
2010 Standout
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
1992
Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines
1999 Standout
The Biosynthetic Logic of Polyketide Diversity
2009 Standout
Carboplatin alone compared with its combination with epirubicin and cyclophosphamide in untreated advanced epithelial ovarian cancer: a hellenic co-operative oncology group study
1996
High-Dose Platinum versus Standard Dose in Advanced Ovarian Carcinoma: A Randomized Trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC)
2000
Cancer of the Ovary
2004 Standout
Analysis of oncogene alterations in human endometrial carcinoma: Prevalence of ras mutations
1991
Moderate progress for ovarian cancer in the last 20 years: prolongation of survival, but no improvement in the cure rate
2002
A Phase I Study of Recombinant Adenovirus Vector-Mediated Delivery of an Anti-erbB-2 Single-Chain (sFv) Antibody Gene for Previously Treated Ovarian and Extraovarian Cancer Patients. University of Alabama at Birmingham, Birmingham, Alabama
1997
What is the optimal goal of primary cytoreductive surgery for bulky stage IIIC epithelial ovarian carcinoma (EOC)?
2006
ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
2005 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Binding of Ovarian Cancer Antigen CA125/MUC16 to Mesothelin Mediates Cell Adhesion
2004 Standout
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity
1986
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer
1998
Pathologic findings from the national surgical adjuvant breast project. Correlations with concordant and discordant estrogen and progesterone receptors
1987
Current Management Strategies for Ovarian Cancer
2007
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Carboplatin versus cisplatin
1993
Dose intensity analysis of chemotherapy regimens in ovarian carcinoma.
1987
INTRAPERITONEAL CHEMOTHERAPY
1994
Advanced Ovarian Cancer: Long-Term Results of Treatment with Intensive Cisplatin-Based Chemotherapy of Brief Duration
1988
Intraepithelial CD8+tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
2005 Standout
Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study
2000
Cancers of the anogenital region in renal transplant recipients: Analysis of 65 cases
1986
Clinical and echocardiographic features of right atrial masses
1984
Disturbance of Tumor Necrosis Factor Alpha-Mediated Beta Interferon Signaling in Cervical Carcinoma Cells
2002 StandoutNobel
Original article: Five year follow-up and dose delivery analysis of cisplatin, iproplatin or carboplatin in combination with cyclophosphamide in advanced ovarian carcinoma
1990
Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial
2003 Standout
Recurrent Epithelial Ovarian Carcinoma: A Randomized Phase III Study of Pegylated Liposomal Doxorubicin Versus Topotecan
2001 Standout
Adjuvant Chemotherapy for Soft Tissue Sarcomas
1991
The Effects of Plant Flavonoids on Mammalian Cells:Implications for Inflammation, Heart Disease, and Cancer
2000 Standout
Breast cancer estrogen and progesterone receptor values: their distribution, degree of concordance, and relation to number of positive axillary nodes.
1983
Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer
2006 Standout
Adjuvant Chemotherapy for Soft Tissue Sarcomas
1995
Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.
1992
Intraperitoneal treatment and dose-intense therapy in ovarian cancer
1999
Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (hac) vs. cisplatin, adriamycin, cyclophosphamide (pac) in advanced ovarian cancer: long-term results
1991
Germ Cell Tumors
1992
Five‐year survival for cisplatin‐based chemotherapy versus single‐agent melphalan in patients with advanced ovarian cancer and optimal debulking surgery
1991
Staging Procedures, Clinical Management, and Survival Outcome for Ovarian Carcinoma
1993
Chemical Implications for Antitumor and Antiviral Prostaglandins: Reaction of Δ7-Prostaglandin A1 and Prostaglandin A1 Methyl Esters with Thiols
1997 StandoutNobel
Works of Clarence E. Ehrlich being referenced
Inhibition by tiazofurin of inosine 5′-phosphate dehydrogenase (IMP DH) activity in extracts of ovarian carcinomas
1992
Features associated with survival and disease-free survival in early endometrial cancer
1989
Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma.
1989
A comparison of findings at second-look laparotomy with preoperative computed tomography in patients with ovarian cancer
1988
A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study.
1985
A clinical evaluation of chlorhexidine gluconate spray as compared with iodophor scrub for preoperative skin preparation.
1984
Second-look laparotomy after chemotherapy in the management of ovarian malignancy
1985
Treatment of Advanced Epithelial Ovarian Cancer using Cisplatin, Adriamycin and Cytoxan—The Indiana University Experience
1983
An Amylase-Producing Serous Cystadenocarcinoma of the Ovary
1985
Bowenoid dysplasia of the vulva
1982
Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy
1984
Intravenous leiomyomatosis of the uterus with extension into the heart
1980
Adenocarcinoma corpus et colli: Analysis of diagnostic variables
1986
The importance of peritoneal cytology in endometrial carcinoma.
1988
Human papillomavirus deoxyribonucleic acid in lesions of the female genital tract: evidence for type 6/11 in squamous carcinoma of the vulva.
1987
Ovarian Strumal Carcinoid: An Immunocytochemical and Ultrastructural Study of Two Cases
1982
Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary A Gynecologic Oncology Group Study
1983
Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix
1983
Relationship between steroid receptors and response to endocrine therapy and cytotoxic chemotherapy in metastatic breast cancer
1980
A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A gynecologic oncology group study
1986
Cytoplasmic progesterone and estradiol receptors in normal, hyperplastic, and carcinomatous endometria: Therapeutic implications
1981